Phase Forward Signs Multi-Year Agreement with Quotient Clinical
Waltham, MA
Phase Forward, a provider of data management solutions for clinical trials and drug safety, announced a multi-year agreement with Quotient Clinical, which specializes in early development services for a broad range of pharmaceutical and biotech customers.
Quotient Clinical, a strategic business unit of Quotient Bioresearch ("Quotient"), is implementing Phase Forward's InForm(tm) Global Trial Management (GTM) electronic data capture (EDC) solution to support data collection, management and analysis for its clinical trials. In addition, the company will use Phase Forward's Central Designer(tm) module to enhance eCRF design efficiency and improve workflow in the study development process for EDC trials.
By supporting faster accessibility and greater visibility into trial data, the EDC implementation will help Quotient to expand its full-service, in-house Biometrics offering, according to the company. In addition, Quotient plans to offer customers on-line access to trial data, making it easier for them to track progress to date or to review summary reports.
"The organization [Quotient] joins the growing number of CROs adopting our InForm product as part of a broader initiative to automate and streamline their Clinical Research Units," said Steve Powell, senior vice president, Phase Forward.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
